Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2001

View Archived Issues

Pravastatin highlighted at ACC scientific sessions

Welfide and Mitsubishi-Tokyo Pharmaceuticals to merge

FDA requests additional information to support Bexxar BLA

Leiras and Nycomed Pharma create joint venture

Ligand updates Targretin development programs in NSCLC, breast cancer and psoriasis

BNP levels reliably detect LV dysfunction in diabetics

MediGene's NV-1020 shows good safety profile in phase I

Experiments in human arteries suggest potential of SLV-306 in CHD

Medco's new stress imaging agent induces coronary hyperemia with few adverse effects

AstraZeneca's Nexium for erosive esophagitis launched in U.S.

L-Arginine has beneficial effects in a range of cardiovascular disorders

Roche seeks FDA approval for Xenical as adjunct in type 2 diabetes

First well-controlled trial of cardiovascular gene therapy discussed at late-breaking ACC session

Novel NK2 antagonist effective in guinea pig models of asthma symptoms

KAD-1229 more effective than nateglinide or voglibose against postprandial hyperglycemia

Calyx commences phase II trial of CLX-0901 in type 2 diabetes

OPC-51803, a new vasopressin V2 agonist, characterized in dogs

Development of Immunex's Enbrel for CHF halted

Versicor begins phase III trial with V-echinocandin for treatment of esophageal candidiasis

ACC news: halofuginone reduces neointimal hyperplasia in response to coronary stenting in pigs

Multiple-cytokine fusion proteins prepared at Lexigen for use in cancer

Anxiolytic isoquinolines disclosed by Egis researchers

Two patents issued to Novuspharma cover new antitumor agents

Biochemie presents new antibacterial mutilin derivatives

Cyclic and acyclic amine derivatives under study at Vertex for use in neurological disorders

Aventis antitumor agents act by inhibiting Ras farnesylation

Hungarian scientists claim new series of heterocyclic angiogenesis inhibitors

Neuropeptide Y receptor antagonists designed at Ortho-McNeil

Morphochem and Aventis to develop novel diabetes treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...